JUL 08, 2019 3:35 PM PDT

This Ovarian Cancer Drug Prolongs Life

WRITTEN BY: Julia Travers

Niraparib is a drug and a PARP inhibitor that targets cancer cells without harming others. PARP inhibitors keep PARP -- proteins that fix damaged DNA in cancer cells -- from doing their job. When PARP inhibitors work well, cancer cells’ cannot repair themselves and can die. These inhibitors are especially effective in ovarian cancer patients who have BRCA mutations. This is because women with these mutations have a condition called homologous recombination deficiency, in which cancer cells struggle to repair mistakes made in the process of dividing. PARP inhibitors make the repair process even more difficult for the cancer cells. But, even some women without a BRCA mutation have homologous recombination deficiency, so they can benefit from a PARP inhibitor like niraparib, as well. Most women with ovarian cancer do not have the BRCA mutation.

Cells dividing

A new study examines the effectiveness of niraparib for women without the BRCA mutation who have undergone multiple rounds of chemotherapy. The study found a longer survival time was possible for these patients.

"There haven't been a lot of studies done on patients without BRCA mutations who have received four, five, six or more lines of chemotherapy. That's who this trial sought to study,” Gynecologic oncologist Kathleen Moore, M.D., said. She is the associate director of clinical research at the Stephenson Cancer Center at OU Medicine and the lead author for the study, which was published in The Lancet Oncology in May 2019.

About 27 percent of the women in the study who responded to their last chemotherapy treatment responded well to niraparib, with an average of more than nine months until the disease grew or spread. Participants in the study had an overall survival time of more than 20 months. Moore points out that any extra time is important for people with cancer. It gives them the opportunity to have more life experiences and, potentially, to stabilize and try a different drug or a clinical trial.

 

Ovaries illustration

 

“Our data support expansion of the treatment indication for poly(ADP-ribose) polymerase inhibitors to include patients with HRD-positive ovarian cancer beyond those with BRCA mutations,” the authors conclude.

 

Learn more about PARP Inhibitors in the video below.

 

Source: EurekAlert, The Lancet Oncology

 
About the Author
  • Julia Travers is a writer, artist and teacher. She frequently covers science, tech, conservation and the arts. She enjoys solutions journalism. Find more of her work at jtravers.journoportfolio.com.
You May Also Like
OCT 05, 2020
Health & Medicine
Cannabis Chemotherapy Trial Shows Encouraging Phase II Results
OCT 05, 2020
Cannabis Chemotherapy Trial Shows Encouraging Phase II Results
Even with the best anti-nausea medications one in three patients receiving chemotherapy experiences vomiting, and about ...
OCT 04, 2020
Cancer
Mutations form in specific genomic patterns based on external and internal factors
OCT 04, 2020
Mutations form in specific genomic patterns based on external and internal factors
New research published in Nature Genetics provides insight on the formation of mutations in the genome. Researchers from ...
OCT 08, 2020
Cancer
Oral cancer pain levels indicate metastasis
OCT 08, 2020
Oral cancer pain levels indicate metastasis
A new study from NYU College of Dentistry researchers provides insight as to why patients with metastatic oral cancer ex ...
OCT 20, 2020
Clinical & Molecular DX
Non-coding RNA As A Barometer For Liver Health
OCT 20, 2020
Non-coding RNA As A Barometer For Liver Health
October is liver cancer awareness month — a month dedicated to educating people about the risk factors and prevent ...
NOV 24, 2020
Cancer
Using Restfulness as a Metric for Measuring Sleep Quality and Cardiovascular Risk
NOV 24, 2020
Using Restfulness as a Metric for Measuring Sleep Quality and Cardiovascular Risk
Did you know sleeping is great? Apparently, getting a full eight hours every night can make you look fabulous and solve ...
NOV 27, 2020
Cell & Molecular Biology
UVC Rays May be a Bigger Cancer Risk Than Known
NOV 27, 2020
UVC Rays May be a Bigger Cancer Risk Than Known
The sun emits different kinds of light and rays including visible and ultraviolet (UV) and infrared. Some of those forms ...
Loading Comments...